The short version of Dual agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
=== Development === Sam Levinson's adaptation of the Israeli television series Euphoria created by Ron Leshem was renewed for a third season on February 4, 2022. On September 19, HBO CEO Casey Bloys said the series would not end after the third season. Production of the season was set to start in February 2023. The producers were aiming for a late 2023 release. However, according to a Vogue interview with Lexi's actress Maude Apatow, filming was set to start in the second half of 2023. On a podcast, series costume designer Heidi Bivens said that preparations would begin in May 2023, with filming starting in June. The season's production was one of many disrupted by the 2023 Writers Guild of America strike. Co-producer for half the episodes of season 2, Jeremy O. Harris spoke on the impact it had on the season with Variety, "He's not a scab. David Zaslav [Warner Bros. Discovery CEO], make a deal. That's what I'll say about season 3 of Euphoria. Make a deal, David. It's easy. Just come to that table." Pre-production for the third season had begun by December 2023. On March 12, 2024, Sydney Sweeney said in an MTV interview with Josh Horowitz that filming for the third season was due to "start soon". But on March 25, it was reported that shooting was postponed indefinitely amid speculation that the series would not return. On July 12, HBO announced that cast members had signed on for a third season that would aim for a January 2025 start date.
HC-toxin, cyclo(D-Pro-L-Ala-D-Ala-L-Aeo), where Aeo is 2-amino-8-oxo-9,10-epoxy decanoic acid, is a virulence factor for the fungus Cochliobolus carbonum on its host, maize. Elamipretide, (D-Arg-dimethylTyr-Lys-Phe-NH2) a drug candidate that targets mitochondria.
Even more surprising, the researchers determined that the girl's mother's genome was more closely related to Western European Neanderthal DNA, excavated thousands of miles away at the Vindija Cave, Croatia, than the Neanderthals who lived in the Siberian cave where her daughter's remains were found. This finding suggests that Neanderthals migrated in multiple waves from Western Europe to Central Eurasia and encountered the Denisovans several times over a span of tens of thousands of years, and possibly coexisted with them for periods of time.
Sources: en.wikipedia.org
After Cuenca, where they attended bullfights, the travelers proceeded to Loja to study the cinchona tree, the source of quinine. They spent nearly three weeks exploring the Amazon headwaters near Jaen, Peru, then crossed the Andes again near Cajamarca, where he spent five days visiting relics linked to the Inca ruler’s capture and execution by the Spanish, including the supposed execution stone and the room where Atahualpa offered gold for his freedom.. At this point, Humboldt’s measurement of Earth’s magnetic intensity provided a benchmark for future geomagnetic studies, as they crossed the magnetic equator. By October 1802, after extensive travel in the Andes, the expedition reached sea level at Trujillo and arrived in Lima on 23 October 1802. Humboldt’s impressions of Lima were largely unfavorable. In a letter dated January 18, 1803, addressed to the Governor of Jaén, he described Lima as having declined significantly compared to other South American cities such as Buenos Aires, Santiago de Chile, and Arequipa. He observed an absence of well-furnished homes and well-dressed women, attributing the city’s poverty to economic conditions and widespread gambling. Public amusements were limited to a theater and an attractive bullring. Humboldt noted that nighttime travel by carriage was hindered by stray dogs and donkey carcasses obstructing the streets. He criticized the prevalence of gambling and family separation, which he believed disrupted social cohesion, and remarked on the lack of large social gatherings.
The cross helical fiber arrangement of the two dermal fibers types collagen and elastin, are responsible for the mechanical properties of the skin such as the two dimensional stiffness seen in the eel skin. In the longitudinal direction, eel skin behaves like a pure fiber system, with a lessertensile strength than skin in the hoop direction. The skin in the hoop direction exhibits a higher elastic modulus than the skin in the longitudinal direction. The two dimensional stiffness allows for the body of the eel to be modeled a pressurized cylinder with the fiber angle of the cross helical arrangement dictating the method by which the eel moves. Eel skin behaves like skin having a fiber angle greater than 45°. In an eel with the cross helical fiber arrangement, muscle contraction in the anterior region bends the fish, and so the skin on the convex side is extended in the longitudinal direction. The extension in the longitudinal direction produces contraction in the hoop direction as the fiber angle decreases until these dimensional changes are resisted by the body of the eel. The skin becomes skin, and additional longitudinal force (applied by skin) results in force being transmitted along the tail. Therefore, changes in fiber angle of the cross helical arrangement in eel skin allows for the transmission of force through the skin during swimming. The skin act like an external tendon allowing for an eel to generate a greater propulsive force per muscle contraction.
== Physical and chemical properties == Lipoic acid contains two sulfur atoms connected by a disulfide bond in the 1,2-dithiolane ring. It also carries a carboxylic acid group. It is considered to be oxidized relative to its acyclic relative dihydrolipoic acid, in which each sulfur exists as a thiol. It is a yellow solid. (R)-(+)-lipoic acid (RLA) occurs naturally, but (S)-(-)-lipoic acid (SLA) has been synthesized. For use in dietary supplement materials and compounding pharmacies, the USP established an official monograph for R/S-LA.
Sources: en.wikipedia.org
Hardtack is a mainstay in parts of Canada. Purity Factories is one maker of traditional hardtack. They specialize in a high density, high caloric product that is well suited for use by expeditions. Located in St. John's, Newfoundland and Labrador, they currently produce three varieties of hardtack:
An injector pen consists of a chamber or cartridge of medication, a tip to attach a needle, and a piston or plunger to inject the dose. Some pens, including most insulin pens, include dials to adjust the dose of the injection before each administration. Dials enable more accurate dose measuring than traditional vial and syringe administration, especially for low doses of insulin. Injector pens which have dials to adjust dosages may also include a clicking sound or other method to confirm the dose adjustment. Some pens may include a cartridge filled with medication which can be replaced when empty to enable reuse of the pen itself, whereas other pens are designed to be disposed of after their prefilled chamber is depleted. Injector pens designed for single use may also be autoinjectors, which do not require the user to press a plunger to inject the dose.
The Australian Football League (AFL) started in 1897 and was originally called the Victorian Football League until its name change in 1990 due to its expansion to other Australian states. AFL is often viewed as an iconic Australian sport which attracts large crowds averaging 35,000 people per game. Drugs are usually known as a chemical compound that has an effect on a person's body in some way, either physically or psychologically. Drugs specific to elite sports, such as AFL, can include anabolic steroids and stimulants due to their performance-enhancing effects. The consumption of these drugs is known as doping. Doping is the administration of drugs to enhance the performance of a person or athlete. This can create unfair advantages in the game and also could lead to many health risks to the players that are doping. The AFL also has practices in place related to the use of illicit recreational drugs.
Several Latin American and Caribbean countries have, at times, faced allegation governments involvement in the illegal drug trade the 1970s and 1980s.In 1978 and 1980, so called "cocaine coups" in Honduras and Bolivia brought such governments to power that were linked to drug trafficking networks (see illegal drug trade in Honduras and illegal drug trade in Bolivia). In Panama, Manuel Noriega, a long-term drug trafficker, served as a head of military from 1983 to 1989, during which he maintained ties with the CIA. The Colombian parapolitics scandal revealed links between parts of the Colombian establishment and the United Self-Defense Forces of Colombia (AUC), a paramilitary group responsible for killing tens of thousands of Colombian civilians, which controls over 75% of the Colombian cocaine trade. The illegal drug trade in Peru was until 2000 shaped by Vladimiro Montesinos's involvement; he had been head of the country's intelligence service since 1990. In 2010 it was alleged that the Mexican Sinaloa cartel had used bribery to co-opt the federal government and focus the government's anti-drug efforts on its competitors. According to Peter Dale Scott, "The Guadalajara Cartel, Mexico's most powerful drug-trafficking network in the early 1980s, prospered largely because it enjoyed the protection of the DFS, under its chief Miguel Nazar Haro, a CIA asset." Now, in the 21st century, there are still major issues with government corruption in Latin America.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。